Autopsy report · NCT00529113

Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer

Cause of deathFunding or business Automatic label, confidence 0.9, unverified. How labels are made.

“To pursue other indications”

The sponsor’s own words in the registry.

Life of this trial

Ran for about 2 years 1 month before it stopped.
33 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 1
Sponsor: Biogen
Sponsor type: Industry
Conditions: Pancreatic Neoplasms; Pancreatic Cancer
Interventions: Bardoxolone methyl; Bardoxolone methyl; Bardoxolone methyl; Bardoxolone methyl; Bardoxolone methyl; Bardoxolone methyl
Participants: 33
Sites: 5
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.